- Home
- IMRX vs CUE Comparison
IMRX vs CUE Comparison
Compare IMRX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- CUE
- Stock Information
- Founded
- IMRX 2008
- CUE 2014
- Country
- IMRX United States
- CUE United States
- Employees
- IMRX N/A
- CUE N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- IMRX Health Care
- CUE Health Care
- Exchange
- IMRX Nasdaq
- CUE Nasdaq
- Market Cap
- IMRX 73.2M
- CUE 64.4M
- IPO Year
- IMRX 2021
- CUE 2018
- Fundamental
- Price
- IMRX $1.94
- CUE $1.50
- Analyst Decision
- IMRX Buy
- CUE Strong Buy
- Analyst Count
- IMRX 7
- CUE 5
- Target Price
- IMRX $12.60
- CUE $5.00
- AVG Volume (30 Days)
- IMRX 369.8K
- CUE 923.5K
- Earning Date
- IMRX 11-13-2024
- CUE 11-19-2024
- Dividend Yield
- IMRX N/A
- CUE N/A
- EPS Growth
- IMRX N/A
- CUE N/A
- EPS
- IMRX N/A
- CUE N/A
- Revenue
- IMRX N/A
- CUE $8,295,000.00
- Revenue This Year
- IMRX N/A
- CUE $104.81
- Revenue Next Year
- IMRX N/A
- CUE N/A
- P/E Ratio
- IMRX N/A
- CUE N/A
- Revenue Growth
- IMRX N/A
- CUE 363.67
- 52 Week Low
- IMRX $1.00
- CUE $0.45
- 52 Week High
- IMRX $8.89
- CUE $3.25
- Technical
- Relative Strength Index (RSI)
- IMRX 51.04
- CUE 50.94
- Support Level
- IMRX $1.68
- CUE $1.32
- Resistance Level
- IMRX $1.97
- CUE $1.99
- Average True Range (ATR)
- IMRX 0.13
- CUE 0.29
- MACD
- IMRX -0.01
- CUE -0.04
- Stochastic Oscillator
- IMRX 71.72
- CUE 26.58
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.